Lebrikizumab
As of the edition of 20 October 2026, Lebrikizumab is an antibody: marketed, first approved in 2023 (EU); acts on IL13; US protection ends in 2036.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Antibody
- Brand name
- Ebglyss
- First approved
- 16 November 2023 (EU)
- Approvals on record
- 8 in 5 regions
- Holder of the most recent approval
- Eli Lilly; 2 holders in all
- Registered trials
- 46, 2 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Inherited and neonatal; Lungs and airways; Blood and lymph; Cancer
US protection
US protection ends in 2036.
US protection ends in 2036, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Eli Lilly. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Lebrikizumab.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL13 | Interleukin-13 | P35225 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 14 | 12 | 1 | 0 |
| Phase 3 | 24 | 17 | 5 | 2 |
| Phase 4 | 3 | 0 | 3 | 0 |
| All trials | 46 |